MiNK Therapeutics Says First Patients In Randomized Phase 2 C-1300-02 Trial Of agenT-797 Alive At Day 28 With Improved Oxygenation, ARDS Resolution, Vasopressor Liberation

Benzinga Newsdesk www.benzinga.com Positive 94.3%

Neg 0% Neu 0% Pos 94.3%

Comments

No comments yet. Be the first!